Impact of COVID-19 on global HCV elimination efforts
Sarah Blach(Center for Disease Analysis), Antonio Craxı̀(University of Palermo), Zongzhen Cai(Center for Disease Analysis), Chris Estes(Center for Disease Analysis), Siya Ma(Center for Disease Analysis), Ivane Gamkrelidze, Stefan Zeuzem(Goethe University Frankfurt), Jean–Michel Pawlotsky(Université Paris-Est Créteil), Devin Razavi‐Shearer(University of Health Sciences Antigua), Alessio Aghemo, Homie Razavi(Center for Disease Analysis), Imam Waked(Menoufia University), Ellen Dugan(Center for Disease Analysis), Loreta A. Kondili(Istituto Superiore di Sanità)
Cited by 279
Related Papers
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821